Diabetes
Diabetes, often marked by prolonged periods of high blood sugar and abnormal lipid levels, can lead to the failure of beta-cells in the pancreas. A key factor in this process is the overactivity of NOX4, an enzyme that produces reactive oxygen species (ROS). These ROS, generated excessively by NOX4, can disrupt the function of mitochondria, the powerhouses of cells.
Glucox Biotech’s selective NOX4 inhibitors, GLX7013114 and GLX7013159, have demonstrated promise in safeguarding these vital beta-cells under diabetic conditions. This breakthrough not only offers hope for better diabetes management but also showcases the potential of targeted treatments in addressing specific disease mechanisms.